A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 309 participants.

Also called NCT01475825

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 309 participants (enrolled count) (from the registry)
Sponsor
Kastle Therapeutics, LLC (from the registry)
Registry
  • NCT NCT01475825
  • EudraCT 2011-001480-42
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Croatia, Czechia, Denmark, Germany, Greece, Hong Kong SAR China, Hungary, India, Israel, Italy, Malaysia, Netherlands, New Zealand, Norway, Poland, Russia, South Africa, South Korea, Spain, Sweden, Taiwan, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01475825. Randomized; quadruple masking; primary purpose treatment. Start 2011-12 (actual); primary completion 2015-12-29 (actual). Results posted on 2019-03-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Acronym
FOCUS FH
Condition
Hypercholesterolemia
Condition
Heterozygous Familial
Intervention (Drug)
mipomersen sodium 200 mg
Intervention (Drug)
Placebo
Intervention (Drug)
mipomersen sodium 70 mg
Lead sponsor
Kastle Therapeutics, LLC (class: industry)

Record details

Record id
cardio:ct-nct01475825
Content hash
121076dead6cbc7835b8c9ee4581246d14dbf8bd7a13c36baaa611f5303c5c1f